Phase 2 Head and Neck Cancer Trial, Recruiting NCT06208826 Sponsor: Tianjin Medical University Cancer Institute and Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT06208826
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the study and are willing to give their informed consent to participate.
  • People aged between 18 and 80 years old, either male or female.
  • People who are generally able to carry out everyday activities with no or minimal limitations, as measured by a standard oncology fitness scale (ECOG score of 0 or 1).
  • People who have been confirmed by laboratory testing (tissue or cell sample) to have squamous cell carcinoma of the head and neck that has not spread to other parts of the body.
  • People whose cancer showed a major reduction (known as a major pathological response) after surgery combined with pre-surgery immunotherapy and chemotherapy treatment.
  • People whose blood, liver, and kidney test results meet specific minimum thresholds, including adequate white blood cell counts, haemoglobin, platelet levels, liver enzyme levels, kidney function, and blood clotting levels (confirm with trial site for exact values).

Who may not be able to join:

  • People whose head and neck squamous cell carcinoma has spread to other parts of the body or cannot be surgically removed.
  • People who have an active autoimmune disease that requires ongoing medical treatment, or who have a history of a severe autoimmune disease.
  • People who have active hepatitis B or C, a known positive HIV test result, or a diagnosis of AIDS.
  • People who have a lung condition such as interstitial pneumonitis, non-infectious pneumonitis, or active tuberculosis of the lungs, or a history of lung tuberculosis that was not successfully treated.
  • People who have an active infection that requires systemic medical treatment.
  • People who have taken part in another clinical trial or received an experimental drug within the 4 weeks before the first dose of this trial, or who are currently enrolled in another clinical trial.
  • People whom the trial investigators consider unsuitable for the study for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +862223340123

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Registry
ClinicalTrials.gov
Start date
1 September 2023
Est. completion
1 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov